1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Manhattan Scientifics, Inc.

Manhattan Scientifics, Inc.

MHTX
Manhattan Scientifics, Inc.US flagOther OTC
0.00
USD
- -
- -
11,186.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
- -
- -
-0.01
0.02
-0.01
- -
-0.02
- -
0.01
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
-0.01
0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.13
-0.13
-0.13
-0.13
-0.1
-0.11
-0.11
-0.13
-0.12
-0.12
-0.12
-0.13
-0.13
-0.13
Tangible Book Value per Share
- -
- -
-0.01
- -
0.01
- -
0.02
- -
- -
0.01
- -
- -
-0.01
-0.01
Basic Weighted Avg Shares
426
450
461
486
522
535
534
534
549
558
559
559
559
559
Sales/Revenue/Turnover
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-315.87
-238.1
-277.3
-541.28
-9,767.19
-4,255.33
-1,604.23
- -
-1,056.7
-1,350
-1,374
-1,358
- -
- -
Depreciation Expense
- -
- -
- -
- -
1
1
1
1
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-2
-4
8
-6
2
-8
-1
4
-4
-3
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-332.9
-301.59
-295.71
-592.68
12,518.75
-4,072
1,088.73
- -
-1,259.79
8,628
-7,278
-5,460
- -
- -
Working Capital
-1
-1
-1
1
4
-1
-1
-2
-2
- -
-1
-1
-2
-2
LT Debt
1
- -
1
2
2
2
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
-1
-2
-1
9
3
8
- -
-1
5
1
-2
-3
-3
Return on Invested Capital (%)
- -
- -
- -
- -
-95.42
- -
-34.26
- -
- -
-35.06
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-15.5
- -
-2.63
- -
- -
-6.54
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
559
559
559
Market Capitalization
1
2
1

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-143.42%
-53.59%
68.73%
Free Cash Flow
-52.47%
-16.98%
-45.56%
Net Income, GAAP
-195.89%
-161.01%
-57.33%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Emmanuel Tsoupanarias
Full Time Employees
1
Sector
Healthcare
Industry
Medical - Devices
Address
244 Fifth Avenue New York City NY United States of America 10001
IPO Date
Jan 6, 1998
CIK
0001099132
Website
mhtx.com
Similar Companies
Varex Imaging Corporation (VREX)
Vivani Medical, Inc. (VANIW)
ViewRay, Inc. (VRAY)
Coloplast A/S (COLO-B.CO)
Perimeter Medical Imaging AI, Inc. (PYNKF)
NIOX Group Plc (NIOX.L)
Business
Manhattan Scientifics, Inc. (MHTX) operates as a technology incubator that acquires, develops, and commercializes life-enhancing technologies focused on nano-technologies and nano-medicines; core offerings include nanostructured bulk metals and alloys in rod, bar, wire, and foil forms for medical implants and prosthetics via its Metallicum unit, as well as precision iron oxide nanoparticles such as NanoMRX for cancer detection and MRI applications formerly advanced through its Senior Scientific division. The company maintains ownership stakes exceeding 50 million shares in Imagion Biosystems Ltd. (ASX: IBX), its spun-off subsidiary specializing in magnetic nanoparticle-based early cancer diagnostics like the MagSense HER2 system granted FDA breakthrough device designation. Founded in 1992 by Marvin Maslow and headquartered at 244 Fifth Avenue in New York, New York, Manhattan Scientifics targets healthcare sectors including oncology and medical devices, with operations spanning the United States and historical ties to Los Alamos National Laboratory; it serves pharmaceutical firms, dental implant manufacturers, and medical metals suppliers through licensing agreements. Recent developments encompass a 2019 exclusive licensing deal for its patented nano-metals technology with a major U.S. metals manufacturer, yielding staged seven-figure payments over four years plus royalties, and ongoing advancements via Imagion including FDA-confirmed clinical trial preparations and nanoparticle supply orders from partners like NewPhase Ltd.; however, the company filed for Chapter 7 bankruptcy in April 2025 amid operational challenges.